Arrowhead Pharmaceuticals Inc. (ARWR) Income Statement

Click line-items for a historical chart and %

Consolidated Statements Of Operations
REVENUE	39.58K
OPERATING EXPENSES
Salaries	4.11M
General and administrative expenses	2.28M
Research and development
Stock-based compensation
Patent amortization
TOTAL OPERATING EXPENSES	19.38M
OPERATING LOSS	-19.34M
OTHER INCOME (EXPENSE)
Loss on equity of investments - Nanotope
Gain on sale of stock in subsidiary
Loss on sale of fixed assets, net	0
Realized and unrealized gain (loss) on marketable securities
Interest income (expense), net
Change in value of derivatives	-113.36K
TOTAL OTHER INCOME (EXPENSE)	-79.26K
LOSS FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	-19.42M
Provision for income taxes
LOSS FROM CONTINUING OPERATIONS
Income (loss) from discontinued operations
Gain (loss) on disposal of discontinued operations
NET INCOME (LOSS) FROM DISCONTINUED OPERATIONS
NET INCOME (LOSS)	-19.42M
Net (income) loss attributable to noncontrolling interests
NET INCOME (LOSS) ATTRIBUTABLE TO ARROWHEAD	-19.42M
Earnings per share - basic:
Income (loss) from continuing operations attributable to Arrowhead common shareholders
Income from discontinued operations attributable to Arrowhead common shareholders
Net income (loss) attributable to Arrowhead shareholders
Weighted average shares outstanding
Earnings per share - diluted:
Income (loss) from continuing operations attributable to Arrowhead common shareholders
Income from discontinued operations attributable to Arrowhead common shareholders
Net income (loss) attributable to Arrowhead shareholders
Weighted average shares outstanding

Entities mentioned with ARWR